JP2000506130A - 抑制性のt細胞反応を誘導するためのdnaワクチン接種 - Google Patents
抑制性のt細胞反応を誘導するためのdnaワクチン接種Info
- Publication number
- JP2000506130A JP2000506130A JP9530370A JP53037097A JP2000506130A JP 2000506130 A JP2000506130 A JP 2000506130A JP 9530370 A JP9530370 A JP 9530370A JP 53037097 A JP53037097 A JP 53037097A JP 2000506130 A JP2000506130 A JP 2000506130A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- mammalian host
- variable region
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.哺乳動物宿主内で活性を有するプロモーターの調節的制御下にある炎症誘発 性のTh1型T細胞反応に関連したT細胞受容体の可変領域の少なくとも一部をコー ドする配列を含むDNA発現カセットを、該発現カセットが該宿主の細胞に組み込 まれて該配列が発現するような条件下で、哺乳動物宿主へ導入する段階を含む、 哺乳動物宿主におけるTh1型T細胞反応の有害効果を低減させるための方法であっ て、 天然型の該T細胞受容体可変領域を発現する該哺乳動物宿主内に存在するT細胞 がTh2型サイトカインを産生し、それによって該Th1型反応の有害効果が低減され る方法。 2.炎症誘発性のTh1型T細胞反応が自己免疫疾患と関連している、請求項1記載の 方法。 3.発現カセット中に存在するT細胞受容体可変領域が自己抗原を特異的に認識す るものである、請求項2記載の方法。 4.自己免疫疾患が脱髄疾患である、請求項3記載の方法。 5.自己抗原がミエリン塩基性蛋白質である、請求項4記載の方法。 6.哺乳動物宿主の筋組織中で活性を有するプロモーターの調節的制御下にある 炎症誘発性のTh1型T細胞反応と関連したT細胞受容体の可変領域の少なくとも一 部をコードする配列を含むDNA発現カセットを、該発現カセットが該宿主の筋細 胞に組み込まれて該配列が発現するような条件下で、哺乳動物宿主の筋組織へ導 入する段階を含む、哺乳動物宿主における自己免疫と関連したTh1型T細胞反応の 有害効果を低減させるための方法であって、 天然型の該T細胞受容体可変領域を発現する該哺乳動物宿主内に存在するT細胞 がTh2型サイトカインを産生し、それによって該Th1型反応の有害効果が低減され る方法。 7.導入段階の前に、筋組織へカルジオトキシンを注入する段階をさらに含む、 請求項6記載の方法。 8.プラスミドがDNA発現カセットを含む、請求項7記載の方法。 9.Th2型サイトカインがIL-4を含む、請求項6記載の方法。 10.哺乳動物宿主の筋組織中で活性を有するプロモーターの調節的制御下にある ミエリン塩基性蛋白質pAc1-20を認識するT細胞受容体の可変領域をコードする配 列を含むDNA発現カセットを、該発現カセットが該宿主の筋細胞に組み込まれて 該配列が発現するような条件下で、哺乳動物宿主の筋組織へ導入する段階を含む 、哺乳動物宿主における脱髄性自己免疫疾患の有害効果を低減させるための方法 であって、 天然型の該T細胞受容体可変領域を発現することを特徴とする、該哺乳動物宿 主の内因性T細胞がTh2型サイトカインを産生し、それによって該自己免疫疾患の 有害効果が低減される方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/606,639 US5939400A (en) | 1996-02-26 | 1996-02-26 | DNA vaccination for induction of suppressive T cell response |
US08/606,639 | 1996-02-26 | ||
PCT/US1997/002837 WO1997030587A1 (en) | 1996-02-26 | 1997-02-24 | Dna vaccination for induction of suppressive t cell response |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000506130A true JP2000506130A (ja) | 2000-05-23 |
Family
ID=24428824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9530370A Ceased JP2000506130A (ja) | 1996-02-26 | 1997-02-24 | 抑制性のt細胞反応を誘導するためのdnaワクチン接種 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5939400A (ja) |
EP (1) | EP0884947B1 (ja) |
JP (1) | JP2000506130A (ja) |
AT (1) | ATE368378T1 (ja) |
AU (1) | AU2135697A (ja) |
CA (1) | CA2247071C (ja) |
DE (1) | DE69737969T2 (ja) |
WO (1) | WO1997030587A1 (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60043624D1 (de) * | 1999-03-12 | 2010-02-11 | Univ R | DNA-Impfung zur Behandlung von Autoimmunerkrankungen |
US7030098B2 (en) * | 1999-03-12 | 2006-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for treatment of autoimmune disease |
US20040131633A1 (en) * | 1999-04-21 | 2004-07-08 | University Of Technology, Sydney | Parasite antigens |
US7329408B2 (en) * | 1999-12-01 | 2008-02-12 | Novartis Vaccines And Diagnostics, Inc. | Eliciting HCV-specific antibodies |
AUPQ520800A0 (en) * | 2000-01-21 | 2000-02-17 | Alfred Hospital | Prime-boost vaccination strategy |
US7462486B2 (en) * | 2000-05-12 | 2008-12-09 | Oregon Health & Science University | Methods of selecting T cell receptor V peptides for therapeutic use |
EP1286664B1 (en) * | 2000-05-12 | 2007-07-25 | Oregon Health and Science University | Combination of low dose estrogen and immunotherapeutic agent for treating immune diseases |
US20030228320A1 (en) * | 2000-08-18 | 2003-12-11 | Ashdown Martin Leonard | Retroviral immunotherapy |
WO2002043774A2 (en) * | 2000-11-02 | 2002-06-06 | Powderject Vaccines, Inc. | Compositions and therapeutical use of polynucleotides encoding tcrs |
BR0208588A (pt) * | 2001-04-12 | 2004-03-23 | Queensland Inst Med Res | Antìgenos para despertar uma resposta imune contra patógenos de ehrilichieae e rickettsieae |
US20040048822A1 (en) * | 2001-11-01 | 2004-03-11 | Juan Harrison | Nucleic acid immunization |
CN101670119A (zh) * | 2001-11-21 | 2010-03-17 | 利兰·斯坦福青年大学托管委员会 | 多核苷酸 |
AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
US6923958B2 (en) * | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
US7094410B2 (en) * | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
CN100546657C (zh) | 2002-11-21 | 2009-10-07 | 贝希尔治疗学股份有限公司 | 预防和治疗疾病的方法及免疫调节核酸组合物 |
JP4931593B2 (ja) | 2003-10-24 | 2012-05-16 | イミュネイド ピーティーワイ リミテッド | 治療の方法 |
EP1786465A4 (en) * | 2004-07-30 | 2009-01-21 | Univ Oregon Health & Science | METHODS FOR DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS |
ATE546733T1 (de) * | 2004-09-08 | 2012-03-15 | Immunaid Pty Ltd | Therapiestrategie zur behandlung von autoimmunkrankheiten und degenerativen erkrankungen |
WO2006052844A2 (en) * | 2004-11-04 | 2006-05-18 | Medical College Of Georgia Research Institute | Tolerogenic vaccine and method |
US20060121031A1 (en) * | 2004-12-07 | 2006-06-08 | Mckenzie Brent S | Relay vaccine |
WO2008148166A1 (en) | 2007-06-08 | 2008-12-11 | Australian Poultry Crc Pty Ltd | Clostridial toxin netb |
CN101970491A (zh) | 2007-08-30 | 2011-02-09 | 沃尔特及伊莱萨霍尔医学研究院 | 树突状细胞标记物及其用途 |
CN103768580A (zh) * | 2007-12-19 | 2014-05-07 | 托勒兰泽亚股份公司 | 治疗自身免疫和过敏性疾病的组合物及方法 |
PT2435825E (pt) | 2009-05-27 | 2015-11-02 | Biotempus Ltd | Métodos para o tratamento de doenças |
WO2011140595A2 (en) | 2010-05-10 | 2011-11-17 | 4G Vaccines Pty Ltd | Immunostimulatory and vaccine compositions |
SE535625C2 (sv) | 2010-10-28 | 2012-10-16 | Toleranzia Ab | Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar |
WO2013059886A1 (en) | 2011-10-28 | 2013-05-02 | Patrys Limited | Pat-lm1 epitopes and methods for using same |
WO2013160865A1 (en) | 2012-04-26 | 2013-10-31 | Toleranzia Ab | Immunotolerizing fusion proteins for treatment of multiple sclerosis |
US20170165347A1 (en) | 2014-06-30 | 2017-06-15 | Murdoch Childrens Research Institute | Helicobacter therapeutic |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992012996A2 (en) * | 1991-01-22 | 1992-08-06 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
-
1996
- 1996-02-26 US US08/606,639 patent/US5939400A/en not_active Expired - Fee Related
-
1997
- 1997-02-24 DE DE69737969T patent/DE69737969T2/de not_active Expired - Fee Related
- 1997-02-24 AU AU21356/97A patent/AU2135697A/en not_active Abandoned
- 1997-02-24 EP EP97906745A patent/EP0884947B1/en not_active Expired - Lifetime
- 1997-02-24 AT AT97906745T patent/ATE368378T1/de not_active IP Right Cessation
- 1997-02-24 CA CA002247071A patent/CA2247071C/en not_active Expired - Fee Related
- 1997-02-24 JP JP9530370A patent/JP2000506130A/ja not_active Ceased
- 1997-02-24 WO PCT/US1997/002837 patent/WO1997030587A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
DE69737969D1 (de) | 2007-09-13 |
EP0884947A1 (en) | 1998-12-23 |
ATE368378T1 (de) | 2007-08-15 |
DE69737969T2 (de) | 2008-04-24 |
EP0884947B1 (en) | 2007-08-01 |
AU2135697A (en) | 1997-09-10 |
US5939400A (en) | 1999-08-17 |
CA2247071A1 (en) | 1997-08-28 |
CA2247071C (en) | 2009-05-19 |
WO1997030587A1 (en) | 1997-08-28 |
EP0884947A4 (en) | 2002-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000506130A (ja) | 抑制性のt細胞反応を誘導するためのdnaワクチン接種 | |
US7579328B2 (en) | DNA vaccination for treatment of multiple sclerosis and insulin-dependent diabetes mellitus | |
US10226517B2 (en) | DNA vaccines encoding heat shock proteins | |
RU2138512C1 (ru) | Вакцина для профилактики или лечения опосредованной т-клетками патологии или нерегулируемой репликации клонами т-клеток, способ выделения вакцины, способ диагностирования или прогнозирования восприимчивости к ревматоидному артриту или рассеянному склерозу, способ профилактики или лечения ревматоидного артрита или рассеянного склероза и содержащий последовательность sgdqggne пептид, являющийся агентом для обнаружения, профилактики или лечения рассеянного склероза | |
US9078843B2 (en) | Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom | |
EP1877090A2 (en) | Trimeric ox40-immunoglobulin fusion protein and methods of use | |
US5985552A (en) | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations | |
EP0722738A2 (en) | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations | |
CA2110055C (en) | T cell receptor peptides as therapeutics for immune-related disease | |
EP1621208B1 (en) | DNA vaccination for treatment of autoimmune disease | |
US7378089B2 (en) | Gene therapy for the prevention of autoimmune disease | |
US20200261576A1 (en) | Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans | |
JP7374502B2 (ja) | Oca-bペプチドコンジュゲート及び処置方法 | |
KR100304042B1 (ko) | 면역-관련 질병용 치료제로서의 t 세포 수용체 펩타이드 | |
van Laar et al. | Towards T cell vaccination in rheumatoid arthritis | |
BG62348B2 (bg) | ваксиниране чрез специфични т-клетъчни популациисрещу заболявания в резултат на патогенни отговори | |
BG63182B2 (bg) | Ваксиниране чрез специфични т- клетъчни популациисрещу заболявания в резултат на патогенни отговори |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070529 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070817 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071128 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080909 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20081015 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081128 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090109 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090420 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090602 |